Inflation-proof stocks: Dominos’ position in the exclusive club is under threat

Nick Sundich Nick Sundich, February 22, 2023

Inflation-proof stocks are inflation-proof until they’re not. Although fast-food companies have been perceived as inflation-proof stocks, this was not true of Dominos (ASX:DMP) in 1HY23. 

 

No time to do stock research, but you still want to invest?

 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 
Dominos no longer belongs to the ‘Inflation-proof stocks’ club

Theoretically, in tough economic times, fast food retailers should perform well as people look for value and they should be inflation-proof stocks.

This rang true for McDonalds during the GFC, not not Dominos. 

Dominos released its 1HY23 result and the company’s EBIT and NPAT both fell by over 21%, coming in at $113.9m and $71.7m respectively.  

Although global sales grew by 1.2% excluding the impact of forex, the statutory result was a 4% decline. Online sales fell by 4.5% as consumers returned to their carry-out habits from before the pandemic. 

Shares in Dominos fell by over 20% at market open, as investors realised that its position as an ‘inflation-proof stock’ was under threat – to say the least. 

 

Dominos Pizza Enterprises (ASX:DMP) share price chart, log scale (Source: TradingView)

 

Dominos goes back to the drawing board

Dominos admitted that its response to combating inflation had not been optimal. The company had thought it could just pass on costs to consumers while retaining the same customer numbers.

It promised shareholders it would provide menu items ‘for more price conscious customers’. This may help with sales, but will do little to help with margins. 

 

 

Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
 
With price targets, buy ranges, stop loss levels and Sell alerts too.

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

Blog Categories

Get Our Top 5 ASX Stocks for FY26

Recent Posts

aml3d

AML3D Surges After Landing 9th US Order with A$1.7m ARCEMY X Deal

AML3D Extends US Momentum, Stock Rises on Major A$1.69m ARCEMY X Sale to FasTech AML3D (ASX: AL3) continues to build…

metallium

Metallium Signs Binding 10 Year Deal with New Frontier Minerals After Record Processing Results

Record FJH Results Drive Metallium’s Binding Ten-Year Deal with New Frontier Minerals Metallium (ASX: MTM) delivered a major step forward…

Prescient Therapeutics

Prescient Therapeutics (ASX:PTX): It has taken the plunge into a Phase 2 trial against T-Cell Lymphoma

There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation.…